AADvac1: Clinical Trials

3 trials of AADvac1, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 unknown. 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 13Completed 2, Unknown 1

Follow AADvac1: new trials by email Literature Review of AADvac1 trials Research Report on AADvac1

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia
AADvac1 40 µg, AADvac1 160 µg - Primary Progressive Nonfluent Aphasia
Phase 1UnknownAxon Neuroscience SE332017-07-312019-11-14
18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease
AADvac1 - Alzheimer's Disease
Phase 1CompletedAxon Neuroscience SE252014-01-012017-03-17
Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease
AADvac1, Placebo - Alzheimer Disease
Phase 1CompletedAxon Neuroscience SE302013-05-012015-10-12

Conditions studied

Alzheimer Disease (2)  ·  Pick Disease of the Brain (2)  ·  Aphasia, Primary Progressive (1)  ·  Dementia (1)  ·  Frontotemporal Dementia (1)  ·  Primary Progressive Nonfluent Aphasia (1)  ·  Tauopathies (1)

Sponsors

Axon Neuroscience SE (3)

Countries

Austria (2)  ·  Germany (1)

Top investigators

Reinhold Schmidt, Professor (2)  ·  Markus Otto, Prof (1)

Results publications

PMID 27955995, PMID 30355322, PMID 25478017

NIH funding

2017 (1)